Barriers to intravenous penicillin use for treatment of nonmeningitis pneumococcal disease.
Infectious disease physicians were surveyed to determine whether the new penicillin breakpoint change will translate into increased penicillin use and to identify barriers to intravenous (i.v.) penicillin use for pneumococcal infections. The inconvenience of i.v. penicillin may limit its use despite a reduction in numbers of infections considered resistant.
Rosen
Jennifer
J
Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. jrosen4@health.nyc.gov
Beekmann
Susan
S
Polgreen
Philip
P
Moore
Matthew
M
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007275:Injections, Intravenous; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage*; D010820:Physicians; D011008:Pneumococcal Infections / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D010406:Penicillins